RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

This early-stage study tests a new mRNA vaccine (IN006) designed to protect against respiratory syncytial virus (RSV). About 240 healthy adults aged 18 and older will receive one of three vaccine doses or a placebo. Researchers will monitor side effects and measure immune respons…

This early-stage study tests an experimental mRNA vaccine designed to protect against respiratory syncytial virus (RSV). Around 213 healthy adults aged 18-45 will receive different doses of the vaccine or a placebo. The main goals are to check for side effects and measure the bod…

This study looks at over 10,000 adults aged 60 and older who already received either an RSV vaccine or a placebo in a previous study. Researchers want to find the best timing for a booster shot and see how long protection lasts over five RSV seasons. Participants who got a placeb…

This study tests an experimental RSV vaccine in adults aged 60 and older. The goal is to see how well the vaccine triggers the immune system, how safe it is, and how long protection lasts—up to 5 years. About 1,720 participants will receive one or more doses to find the best vacc…

This study tests a non-live RSV vaccine in 100 adults who have received a lung or stem cell transplant. The goal is to see if the vaccine is safe and helps their immune system fight RSV, a common virus that can be dangerous for them. Participants will give blood samples and be mo…